Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corp GERN
$1.26
▲ +0.00%
(+$0.00)
Open
$1.26
Prev Close
$1.26
Day Range
$1.24 – $1.27
52W Range
$1.04 – $2.01
Market Cap
$809.52M
Beta
0.57
EPS (TTM)
$-0.10
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1996-07-31 |
| Shares Out. | 641,520,000 |
| Website | geron.com/ ↗ |
| Phone | 13026587581 |
| Employees | 258 |
| Revenue | $57.5M |
| Gross Profit | $48.2M |
| Net Income | -$16.7M |
| Free Cash Flow | -$114.8M |
| Total Assets | $519.0M |
| Total Liabilities | $300.4M |
| Equity | $218.6M |
About Geron Corp
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Geron Corp is a publicly traded company under the ticker symbol GERN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-09-01)